论文部分内容阅读
以低抗凝肝素为来源，按生产要求设计工艺，制备了平均分子量为６０００ｄ的低分子肝素，测定了其理化指标、抗凝效价和抗ＦＸａ活性，研究了其抗血栓形成作用和药代动力学。结果表明，该低分子肝素具有较强的抗ＦＸａ活性和抗血栓形成作用，体内生物半衰期长。
The low-molecular-weight heparin with the average molecular weight of 6000d was prepared by low-heparin as the source, according to the production requirements. The physicochemical indexes, anticoagulant potency and anti-FXa activity were measured. The anti-thrombotic effect and pharmacokinetics dynamics. The results show that the low molecular weight heparin has strong anti-FXa activity and anti-thrombosis effect, and long biological half-life in vivo.